Working… Menu

Bevacizumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00482495
Recruitment Status : Completed
First Posted : June 5, 2007
Last Update Posted : May 11, 2011
National Cancer Institute (NCI)
Information provided by:
Mayo Clinic

Brief Summary:

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Bevacizumab may also stop the growth of multiple myeloma by blocking blood flow to the cancer.

PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with relapsed or refractory multiple myeloma.

Condition or disease Intervention/treatment Phase
Multiple Myeloma and Plasma Cell Neoplasm Biological: bevacizumab Genetic: gene expression analysis Genetic: protein expression analysis Other: laboratory biomarker analysis Phase 2

Detailed Description:



  • Determine the hematologic response rate in patients with relapsed or refractory multiple myeloma treated with bevacizumab.
  • Determine the proportion of patients who are progression free and have not failed treatment after 1 year.


  • Determine the toxicity of this drug in these patient.
  • Determine the time to disease progression in patients receiving this drug.
  • Determine the overall survival and survival at 1 year in patients receiving this drug.

OUTLINE: This is an open-label study.

Patients receive bevacizumab IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Blood samples are obtained for correlative studies at baseline, after course 2, and at 12 weeks. Samples are analyzed for interleukin-6, Flt-1, and VEGF levels.

After completion of study therapy, patients are followed every 3-6 months for up to 3 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 42 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Trial of Bevacizumab in Patients With Relapsed or Refractory Multiple Myeloma
Study Start Date : April 2006
Actual Primary Completion Date : December 2006
Actual Study Completion Date : November 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Multiple Myeloma
Drug Information available for: Bevacizumab

Primary Outcome Measures :
  1. Confirmed hematologic response
  2. Progression-free survival at 1 year

Secondary Outcome Measures :
  1. Toxicity as measured by NCI CTCAE v3.0
  2. Time to progression
  3. Duration of response
  4. Survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of relapsed or refractory multiple myeloma
  • Measurable or evaluable disease as defined by ≥ 1 of the following:

    • Serum monoclonal protein ≥ 1.0 g by protein electrophoresis
    • Monoclonal protein ≥ 200 mg by 24-hour urine electrophoresis
    • Serum immunoglobulin free light chain ≥ 10 mg/dL AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
    • Monoclonal bone marrow plasmacytosis ≥ 30% (evaluable disease)
  • No concurrent amyloidosis


  • ECOG performance status (PS) 0 or 1

    • ECOG PS 2 based on immobility from myeloma bone disease alone allowed at the discretion of treating physician
  • Creatinine ≤ 2.0 mg/dL
  • ANC ≥ 1,000/mm³
  • Platelet count ≥ 75,000/mm³
  • Hemoglobin ≥ 8.0 g/dL
  • Proteinuria ≤ 1 g/dL by 24-hour urine collection (excluding monoclonal protein)
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 4 weeks after completion of study treatment
  • No bleeding diathesis
  • No hypertension (defined as BP > 150/100 mm Hg)
  • No active bleeding, healing or nonhealing wound, ulcer, or bone fracture (excluding fractures secondary to myeloma)
  • No active ulcerative disease including, but not limited to, any of the following:

    • Peptic ulcer disease
    • Ulcerative esophagitis
    • Ulcerative colitis
    • Crohn's disease
  • LVEF ≥ 50% by 2-dimensional ECHO or MUGA scan
  • No NYHA class III or IV heart disease
  • No other active malignancy except for nonmelanoma skin cancer or in situ cervical or breast cancer
  • No active infection
  • No other comorbidity that would interfere with study compliance
  • No transient ischemic attack, cerebrovascular accident, or myocardial infarction within the past year
  • No abdominal fistula, gastrointestinal perforation, or intraabdominal abscess within the past 6 months
  • No significant traumatic injury within the past 28 days


  • See Disease Characteristics
  • No more than 2 prior antimyeloma treatment courses, except for bisphosphonates
  • No standard or experimental drug therapy, other than ongoing bisphosphonate treatment and/or epoetin alfa, within the past 28 days
  • No experimental non-drug therapy within the past 28 days
  • Palliative radiation therapy within the past 28 days allowed provided ≤ 3 sites of bone disease was irradiated
  • No prior bevacizumab or other experimental antiangiogenic agents other than thalidomide or lenalidomide
  • No minor surgical procedures, fine-needle aspiration, or core biopsies within the past 7 days
  • No major surgical procedure or open biopsy within the past 28 days
  • No concurrent corticosteroids

    • Chronic steroids ≤ 20 mg/day (prednisone equivalent) for disorders other than myeloma (i.e., adrenal insufficiency, rheumatoid arthritis) allowed
  • No other concurrent investigational therapy
  • No other concurrent systemic antineoplastic therapy including, but not limited to, the following:

    • Cytotoxic chemotherapy
    • Immunotherapy
    • Hormonal therapy
    • Monoclonal antibody therapy
  • Concurrent bisphosphonates allowed

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00482495

Layout table for location information
United States, Minnesota
Mayo Clinic
Rochester, Minnesota, United States, 55940
Sponsors and Collaborators
Mayo Clinic
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Suzanne Hayman, MD Mayo Clinic

Layout table for additonal information
Responsible Party: Suzanne R. Hayman, M.D., Mayo Clinic Identifier: NCT00482495     History of Changes
Other Study ID Numbers: CDR0000546757
P30CA015083 ( U.S. NIH Grant/Contract )
MC0584 ( Other Identifier: Mayo Clinic Cancer Center )
05-004261 ( Other Identifier: Mayo Clinic IRB )
First Posted: June 5, 2007    Key Record Dates
Last Update Posted: May 11, 2011
Last Verified: May 2011
Keywords provided by Mayo Clinic:
refractory multiple myeloma
stage I multiple myeloma
stage II multiple myeloma
stage III multiple myeloma
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Myeloma
Neoplasms, Plasma Cell
Neoplasms by Histologic Type
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors